We advised Biomatter, a Lithuanian biotechnology startup, on raising USD 18 million in funding.  The company, which uses artificial intelligence to develop novel enzymes, will invest the funds in establishing a new 2,000 m² enzyme development and testing facility in Vilnius, expanding its sales team and strengthening its operations in the US.

The round was led by Astanor, an international venture capital fund specialising in agrifood technology. It was joined by existing Biomatter investors UVC Partners, Inventure and Metaplanet. Practica Capital, a Baltic venture capital fund manager, also took part in Biomatter’s earlier funding rounds in 2021 and 2024.

Biomatter has already developed more than fifty different enzymes, which are used by over 25 companies operating in Europe, the US and Japan. The startup’s clients work in biopharma, diagnostics, agriculture and industrial biotechnology. They include AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos.

“Our goal is to make ordering a custom-designed enzyme as simple as ordering any reagent from a catalogue – even when an enzyme with the required function does not yet exist,” says Laurynas Karpus, CEO and co-founder of Biomatter.

Enzyme engineering programmes that usually take months or even years are already completed by Biomatter within a few weeks. The new facility is expected to reduce enzyme engineering cycles to just days over time.

Our team and services

Our team, consisting of partner Mantas Petkevičius, senior associate Mindaugas Baniulis and associate Rytė Rėčiunaitė, advised the client on all matters related to the investment, from signing the letter of intent to conducting negotiations and drafting the transaction documents.